Health ❯ Healthcare ❯ Vaccines

COVID-19 Vaccines

Vaccine Safety mRNA Vaccines Pfizer Vaccine FDA Approval Eligibility Criteria Novavax Vaccine Moderna Insurance Coverage Moderna Vaccine Novavax Nuvaxovid Public Perception Recommendations mRNA Technology Booster Shots FDA Approvals Vaccine Efficacy Pediatric Vaccination Issues Pfizer and Moderna Vaccines mNEXSPIKE Vaccine Distribution Approval Process Moderna Spikevax Availability and Regulations Off-label Use AstraZeneca Vaccine Vaccine Availability 2024-2025 Vaccine Updates Public Health Implications MRNA Vaccines Novavax Vaccine Concerns Effectiveness Prescription Requirements Vaccine Coverage Comirnaty Mortality Rates Distribution and Administration Myocarditis Risks KP.2 Variant Vaccines Updated Vaccination Guidelines Vaccine Stocks Distribution and Access Pfizer Patient Information Vaccine Updates Eligibility Vaccine Composition Flu Vaccines CDC Recommendations Hydroxychloroquine Novavax Vaccines Vaccine Production Public Health Recommendations Access to Vaccines Vaccine Access Access Issues 2024-2025 COVID Vaccines Omicron Variant Vaccines Vaccine Formulation Updates Children's Vaccination Regulatory Approval Vaccine Hesitancy Regulatory Changes FDA Guidelines Emergency Use Authorization Immune Response Regulatory Issues Safety Concerns Advisory Recommendations Covishield Patient Access XFG Vaccine Distribution Regulations Vaccine Development Efficacy and Safety Variants Pfizer-BioNTech Vaccines Pfizer/BioNTech COMIRNATY XFG Administration Moderna COVID Vaccine Pharmacy Services Moderna mNEXSPIKE Novavax COVID-19 Vaccine Novavax Protein Vaccine Thrombosis with Thrombocytopenia Syndrome Omicron Variants Pharmacy Regulations Military Health Policies Myocarditis Combined Vaccines Pediatric Vaccination XFG Variant Access and Policy mCombriax Nuvaxovid Medical Recommendations Omicron Subvariants Guidance Changes Regulatory Environment Access to Vaccination Research

FDA Approves XFG-Targeted COVID Vaccines for Older and High‑Risk Americans

Manufacturers are shipping doses now while formal CDC season guidance is unresolved, leaving access and coverage rules to states and providers.

Moderna Posts Q2 Revenue Beat as Norovirus Trial Misses Interim Goal

Fauci Diaries Released Show June 2021 Pulmonary Infarction

FDA Advisers Recommend XFG as Target for 2026–2027 COVID-19 Vaccines

Moderna Beats Q1 Forecast as Overseas COVID Shot Sales Rebound

Court Freeze of U.S. Vaccine Panel Puts New Shots, Coverage in Limbo

Hemmati Emerges as Front-Runner to Lead FDA’s Vaccine and Biologics Center

EU Regulators Back First Combined COVID-19 and Flu mRNA Shot for Adults 50 and Over

Moderna Beats Q4 Estimates, Reaffirms 2026 Outlook as FDA Blocks U.S. Flu Filing

NEJM Study Identifies Viral Protein and Antibody Mutation Behind Rare Vaccine‑Linked Clots

Former FDA Chiefs Rebuke Leaked Memo Claiming COVID Shots Killed 10 Children, Warn of Risky Vaccine Overhaul

Moderna Trims 2025 Forecast as Q3 Loss Narrows and Revenue Beats

JAMA Study Finds 2024–2025 COVID Vaccines Reduce Severe Illness, With Protection Waning by 20 Weeks

Pharmacies’ Booking Rules Collide With States’ Broader COVID Shot Access After ACIP Shift

States Broaden Access to Updated COVID-19 Shots as Federal Limits Create Patchwork

Massachusetts Becomes First to Require Coverage of State-Recommended Vaccines

Pharmacies Curb COVID Vaccines as States Race to Keep Access After FDA Narrows Approval

FDA Narrows Covid Vaccine Eligibility, Prompting Pharmacy Restrictions in Many States

FDA Weighs Ending Pfizer COVID-19 Authorization for Children Under 5

Moderna Beats Q2 Estimates But Cuts 2025 Outlook After U.K. Delay